Granules Pharmaceuticals Recalls Gabapentin Tablets Due to Metformin Contamination
Granules Pharmaceuticals recalls 600mg Gabapentin tablets (500-count) with metformin tablets found inside. Consumers should check lot numbers and contact the company for details.
Lower-risk recall
Presence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin Tablets
Contact the company
What happened, in plain English
Granules Pharmaceuticals is recalling 600mg Gabapentin tablets (500-count bottles) because foreign metformin tablets were found inside. This could cause unintended medication interactions if taken. Read more at govinfonow.com/recall/32578-granules-pharmaceuticals-recalls-gabapentin-tablets-due-to-metformin-contamination.
Source Summary by GovInfoNow · govinfonow.com/recall/32578-granules-pharmaceuticals-recalls-gabapentin-tablets-due-to-metformin-contamination · Updated August 17, 2026 · FDA enforcement record: FDA #D-0634-2024
Cite this page
“Granules Pharmaceuticals Recalls Gabapentin Tablets Due to Metformin Contamination.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32578-granules-pharmaceuticals-recalls-gabapentin-tablets-due-to-metformin-contamination. Based on FDA recall #D-0634-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0634-2024%22&limit=1).
Why it’s dangerous
Foreign metformin tablets were found inside the gabapentin bottles. This could cause unintended medication interactions if someone takes both drugs without knowing.
Who’s affected
People who have the 600mg Gabapentin tablets (500-count) with lot number 1380040A manufactured in India. Those taking gabapentin for seizures or nerve pain are most at risk.
How to tell if you have this one
Check for the lot number 1380040A on the bottle. The product was manufactured in India by Granules India Limited and sold in the US by Granules Pharmaceuticals Inc.
- Brand
Granules Pharmaceuticals- Category
Drug
What to do — step by step
Check Product Details
Look for the lot number 1380040A on the bottle label.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 10 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
Is there a risk of serious injury?
The recall is for medication safety, not physical injury risk. No serious injury mechanism is described.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0634-2024 (July 31, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0634-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.